PDF herunterladen
Drug Res (Stuttg) 2016; 66(11): 597-602
DOI: 10.1055/s-0042-112365
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

The Effect of Muscarinic Receptor Modulators on the Antinociception Induced by CB2 Receptor Agonist, JWH133 in Mice

M. Alipour
1   Department of Physiology and Pharmacology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
,
F. Fekrmandi
2   Department of Medicine, McGill University, Montreal, Canada
,
S. Onsori
1   Department of Physiology and Pharmacology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
,
P. Tabrizian
1   Department of Physiology and Pharmacology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
,
M. R. Jafari
1   Department of Physiology and Pharmacology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 30. April 2016

accepted 01. Juli 2016

Publikationsdatum:
09. August 2016 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

There is no published study regarding the interaction between muscarinic receptor modulators and antinociception induced by cannabinoid receptor (CB2) agonist. The effect of pilocarpine (a muscarinic agonist) and atropine (a muscarinic antagonist) on JWH-133 (a CB2 agonist) induced analgesia in mice was studied. First the analgesic effect of JWH-133 (0.001–1 mg/Kg) or pilocarpine (2.5–20 mg/kg) or atropine (0.2–5 mg/kg) was evaluated. Subsequently, the effect of co-administration of pilocarpine (2.5 mg/kg) or atropine (5 mg/kg) and JWH-133 (0.001–1 mg/Kg) were studied too. JWH-133 and pilocarpine provoked antinociception in mice but atropine did not. Pilocarpine potentiated the analgesic effect of JWH-133 but atropine antagonized that. It can be concluded that JWH-133 induced antinociception is affected by muscarinic receptor modulators in mice.

Key words

antinociception - JWH-133 - pilocarpine - atropine - formalin test - mice
 

  • References

  • 1 Jhaveri MD, Sagar DR, Elmes SJ et al. Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 2007; 36: 26-35
    CrossrefPubMedGoogle Scholar
  • 2 Volkow ND, Baler RD, Compton WM et al. Adverse health effects of marijuana use. N Engl J Med 2014; 370: 2219-2227
    CrossrefPubMedGoogle Scholar
  • 3 Deng L, Guindon J, Cornett BL et al. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal. Biol Psychiatry 2015; 77: 475-487
    CrossrefPubMedGoogle Scholar
  • 4 Han S, Thatte J, Buzard DJ et al. Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. J Med Chem 2013; 56: 8224-8256
    CrossrefPubMedGoogle Scholar
  • 5 Ehrhart J, Obregon D, Mori T et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2005; 2: 29
    CrossrefPubMedGoogle Scholar
  • 6 Dittel BN. Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor. Br J Pharmacol 2008; 153: 271-276
    CrossrefPubMedGoogle Scholar
  • 7 Shoemaker JL, Seely KA, Reed RL et al. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 2007; 101: 87-98
    PubMedGoogle Scholar
  • 8 Sagredo O, Pazos MR, Valdeolivas S et al. Cannabinoids: novel medicines for the treatment of Huntington’s disease. Recent Pat CNS Drug Discov 2012; 7: 41-48
    CrossrefPubMedGoogle Scholar
  • 9 Pacher P, Hasko G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 2008; 153: 252-262
    CrossrefPubMedGoogle Scholar
  • 10 Mach F, Montecucco F, Steffens S. Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol 2008; 153: 290-298
    CrossrefPubMedGoogle Scholar
  • 11 Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 2008; 153: 263-270
    CrossrefPubMedGoogle Scholar
  • 12 Feizi A, Jafari MR, Hamedivafa F et al. The preventive effect of cannabinoids on reperfusion-induced ischemia of mouse kidney. Experimental and toxicologic pathology: official journal of the Gesellschaft fur Toxikologische Pathologie 2008; 60: 405-410
    PubMedGoogle Scholar
  • 13 Barutta F, Piscitelli F, Pinach S et al. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 2011; 60: 2386-2396
    CrossrefPubMedGoogle Scholar
  • 14 Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 2008; 57: 1140-1155
    CrossrefPubMedGoogle Scholar
  • 15 Ofek O, Karsak M, Leclerc N et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 2006; 103: 696-701
    CrossrefPubMedGoogle Scholar
  • 16 Huffman JW. CB2 receptor ligands. Mini Rev Med Chem 2005; 5: 641-649
    CrossrefPubMedGoogle Scholar
  • 17 Jafari MR, Golmohammadi S, Ghiasvand F et al. Influence of nicotinic receptor modulators on CB2 cannabinoid receptor agonist (JWH133)-induced antinociception in mice. Behavioural pharmacology 2007; 18: 691-697
    CrossrefPubMedGoogle Scholar
  • 18 Curto-Reyes V, Boto T, Hidalgo A et al. Antinociceptive effects induced through the stimulation of spinal cannabinoid type 2 receptors in chronically inflamed mice. Eur J Pharmacol 2011; 668: 184-189
    CrossrefPubMedGoogle Scholar
  • 19 Mukae T, Uchida H, Ueda H. Donepezil reverses intermittent stress-induced generalized chronic pain syndrome in mice. J Pharmacol Exp Ther 2015; 353: 471-479
    CrossrefPubMedGoogle Scholar
  • 20 Prestifilippo JP, Fernandez-Solari J, de la Cal C et al. Inhibition of salivary secretion by activation of cannabinoid receptors. Exp Biol Med (Maywood) 2006; 231: 1421-1429
    CrossrefPubMedGoogle Scholar
  • 21 Mang CF, Erbelding D, Kilbinger H. Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br J Pharmacol 2001; 134: 161-167
    CrossrefPubMedGoogle Scholar
  • 22 Nieri P, Martinotti E, Testai L et al. R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors. Eur J Pharmacol 2003; 459: 75-81
    CrossrefPubMedGoogle Scholar
  • 23 Baldassano S, Serio R, Mule F. Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle. Eur J Pharmacol 2008; 582: 132-138
    CrossrefPubMedGoogle Scholar
  • 24 Kojima S, Sugiura T, Waku K et al. Contractile response to a cannabimimetic eicosanoid, 2-arachidonoylglycerol, of longitudinal smooth muscle from the guinea-pig distal colon in vitro. Eur J Pharmacol 2002; 444: 203-207
    CrossrefPubMedGoogle Scholar
  • 25 Smid SD, Bjorklund CK, Svensson KM et al. The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon. Eur J Pharmacol 2007; 575: 168-176
    CrossrefPubMedGoogle Scholar
  • 26 Rinaldo L, Hansel C. Muscarinic acetylcholine receptor activation blocks long-term potentiation at cerebellar parallel fiber-Purkinje cell synapses via cannabinoid signaling. Proc Natl Acad Sci USA 2013; 110: 11181-11186
    CrossrefPubMedGoogle Scholar
  • 27 Nakamura-Palacios EM, Amodeo Bueno OF, Takahashi RN et al. Acute or chronic effects of cannabinoids on spontaneous or pharmacologically induced yawning in rats. Pharmacol Biochem Behav 2002; 74: 205-212
    CrossrefPubMedGoogle Scholar
  • 28 Jafari MR, Onsori S, Fekrmandi F et al. Influence of muscarinic receptor modulators on interacerebroventricular injection of arachydonylcyclopropylamide induced antinociception in mice. Physiology & behavior 2015; 138: 273-278
    CrossrefPubMedGoogle Scholar
  • 29 Tjolsen A, Berge OG, Hunskaar S et al. The formalin test: an evaluation of the method. Pain 1992; 51: 5-17
    CrossrefPubMedGoogle Scholar
  • 30 Zimmer A, Zimmer AM, Hohmann AG et al. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 5780-5785
    CrossrefPubMedGoogle Scholar
  • 31 Ibrahim MM, Rude ML, Stagg NJ et al. CB2 cannabinoid receptor mediation of antinociception. Pain 2006; 122: 36-42
    CrossrefPubMedGoogle Scholar
  • 32 Greco R, Mangione AS, Sandrini G et al. Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. J Headache Pain 2014; 15: 14
    CrossrefPubMedGoogle Scholar
  • 33 Wang ZY, Wang P, Bjorling DE. Activation of cannabinoid receptor 2 inhibits experimental cystitis. Am J Physiol Regul Integr Comp Physiol 2013; 304: R846-R853
    CrossrefPubMedGoogle Scholar
  • 34 Ikeda H, Ikegami M, Kai M et al. Activation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice. Neuroscience 2013; 250: 446-454
    CrossrefPubMedGoogle Scholar
  • 35 Gadotti VM, You H, Petrov RR et al. Analgesic effect of a mixed T-type channel inhibitor/CB2 receptor agonist. Mol Pain 2013; 9: 32
    CrossrefPubMedGoogle Scholar
  • 36 Vincenzi F, Targa M, Corciulo C et al. Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models. Pain 2013; 154: 864-873
    CrossrefPubMedGoogle Scholar
  • 37 Berger ND, Gadotti VM, Petrov RR et al. NMP-7 inhibits chronic inflammatory and neuropathic pain via block of Cav3.2T-type calcium channels and activation of CB2 receptors. Mol Pain 2014; 10: 77
    CrossrefPubMedGoogle Scholar
  • 38 Deng L, Guindon J, Vemuri VK et al. The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB(2) receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. Mol Pain 2012; 8: 71
    CrossrefPubMedGoogle Scholar
  • 39 Naik SR, Kelkar MR, Amladi SR et al. Effect of muscimol, a central GABA receptor agonist, on the catalepsy, striatal homovanillic acid increase, and analgesia induced by pilocarpine in rats. Psychopharmacology (Berl) 1981; 74: 393-394
    CrossrefPubMedGoogle Scholar
  • 40 Lewis JW, Cannon JT, Liebeskind JC. Involvement of central muscarinic cholinergic mechanisms in opioid stress analgesia. Brain Res 1983; 270: 289-293
    CrossrefPubMedGoogle Scholar
  • 41 Sperber ES, Kramer E, Bodnar RJ. Effects of muscarinic receptor antagonism upon two forms of stress-induced analgesia. Pharmacol Biochem Behav 1986; 25: 171-179
    CrossrefPubMedGoogle Scholar
  • 42 Hartvig P, Gillberg PG, Gordh Jr. T et al. Cholinergic mechanisms in pain and analgesia. Trends Pharmacol Sci 1989; Suppl: 75-79
    PubMedGoogle Scholar
  • 43 de Oliveira RC, de Oliveira R, Biagioni AF et al. Dorsal raphe nucleus acetylcholine-mediated neurotransmission modulates post-ictal antinociception: The role of muscarinic and nicotinic cholinergic receptors. Brain Res 2015;
    PubMedGoogle Scholar
  • 44 Prado WA, Dias TB. Postoperative analgesia induced by intrathecal neostigmine or bethanechol in rats. Clin Exp Pharmacol Physiol 2009; 36: 648-654
    CrossrefPubMedGoogle Scholar
  • 45 Iwamoto ET, Marion L. Characterization of the antinociception produced by intrathecally administered muscarinic agonists in rats. J Pharmacol Exp Ther 1993; 266: 329-338
    PubMedGoogle Scholar
  • 46 Naguib M, Yaksh TL. Characterization of muscarinic receptor subtypes that mediate antinociception in the rat spinal cord. Anesth Analg 1997; 85: 847-853
    CrossrefPubMedGoogle Scholar
  • 47 Eisenach JC. Muscarinic-mediated analgesia. Life Sci 1999; 64: 549-554
    CrossrefPubMedGoogle Scholar
  • 48 Barocelli E, Ballabeni V, Bertoni S et al. Evidence for specific analgesic activity of a muscarinic agonist selected among a new series of acetylenic derivatives. Life Sci 2001; 68: 1775-1785
    CrossrefPubMedGoogle Scholar
  • 49 Duttaroy A, Gomeza J, Gan JW et al. Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol 2002; 62: 1084-1093
    CrossrefPubMedGoogle Scholar
  • 50 Kender RG, Harte SE, Munn EM et al. Affective analgesia following muscarinic activation of the ventral tegmental area in rats. J Pain 2008; 9: 597-605
    CrossrefPubMedGoogle Scholar
  • 51 Tata AM. Muscarinic acetylcholine receptors: new potential therapeutic targets in antinociception and in cancer therapy. Recent Pat CNS Drug Discov 2008; 3: 94-103
    CrossrefPubMedGoogle Scholar
  • 52 de Freitas RL, Bolognesi LI, Twardowschy A et al. Neuroanatomical and neuropharmacological approaches to postictal antinociception-related prosencephalic neurons: the role of muscarinic and nicotinic cholinergic receptors. Brain Behav 2013; 3: 286-301
    CrossrefPubMedGoogle Scholar
  • 53 Ghelardini C, Malmberg-Aiello P, Giotti A et al. Investigation into atropine-induced antinociception. Br J Pharmacol 1990; 101: 49-54
    CrossrefPubMedGoogle Scholar
  • 54 Spicuzza L, Haddad EB, Birrell M et al. Characterization of the effects of cannabinoids on guinea-pig tracheal smooth muscle tone: role in the modulation of acetylcholine release from parasympathetic nerves. Br J Pharmacol 2000; 130: 1720-1726
    CrossrefPubMedGoogle Scholar